FHTX.US Foghorn Therapeutics Inc

Healthcare Biotechnology USA Stocks
2.07 USD
Close of Nov 14, 2026
1.79 7.61
Market cap
USD 124M
P/E
23.0x
P/B
2,005.35x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is FHTX.US undervalued?

Graham number

The Graham number of Foghorn Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Foghorn Therapeutics Inc fundamental analysis

No fundamental analysis for Foghorn Therapeutics Inc yet.

Foghorn Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; a…

Full company profile